Last reviewed · How we verify

Autologous Platelet-Rich Fibrin

National Children's Medical Center, Uzbekistan · Phase 1 active Biologic Quality 0/100

Autologous Platelet-Rich Fibrin is a Biologic drug developed by National Children's Medical Center, Uzbekistan. It is currently in Phase 1 development.

At a glance

Generic nameAutologous Platelet-Rich Fibrin
SponsorNational Children's Medical Center, Uzbekistan
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Autologous Platelet-Rich Fibrin

What is Autologous Platelet-Rich Fibrin?

Autologous Platelet-Rich Fibrin is a Biologic drug developed by National Children's Medical Center, Uzbekistan.

Who makes Autologous Platelet-Rich Fibrin?

Autologous Platelet-Rich Fibrin is developed by National Children's Medical Center, Uzbekistan (see full National Children's Medical Center, Uzbekistan pipeline at /company/national-children-s-medical-center-uzbekistan).

What development phase is Autologous Platelet-Rich Fibrin in?

Autologous Platelet-Rich Fibrin is in Phase 1.

Related